Perjeta 420mg Injection

Perjeta 420mg Injection (Pertuzumab)

Perjeta 420mg Injection is a recombinant humanized monoclonal antibody that targets the HER2 receptor, a key driver of cancer cell growth in HER2-positive breast cancer. This targeted therapy is primarily used in combination with trastuzumab (Herceptin) and chemotherapy as a first-line treatment for patients with metastatic or early-stage HER2-positive breast cancer.

Mechanism of Action

Pertuzumab binds to a unique site on the HER2 receptor, preventing its dimerization with other HER receptors—particularly HER3. As a result, the drug inhibits downstream signaling pathways responsible for tumor cell growth and survival. This mechanism enhances the effectiveness of trastuzumab, offering a more complete HER2 blockade and improved clinical outcomes.

Approved Indications

• First-line therapy for HER2-positive metastatic breast cancer
• Neoadjuvant treatment for HER2-positive early breast cancer with a high risk of recurrence

Dosage and Administration

The typical regimen starts with a loading dose of 840mg, followed by maintenance doses of 420mg every three weeks via intravenous infusion. The total duration of therapy depends on patient response and disease progression. It is crucial to monitor cardiac function periodically, as HER2-targeted therapies can increase the risk of cardiotoxicity.

Possible Side Effects

Common adverse effects include:

• Diarrhea
• Nausea
• Alopecia (hair loss)
• Fatigue
• Neutropenia
• Rash

Although rare, serious complications such as heart failure or hypersensitivity reactions may occur. Immediate medical attention is necessary if these symptoms appear.

Infusion Monitoring

Infusion-related reactions are typically mild and can be managed with premedication and close observation during and after the infusion session.

Storage Instructions

Keep Perjeta vials refrigerated between 2°C and 8°C. Do not freeze or expose the medication to light.